Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Next Previous
Search
Trial Profile

A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Jul 2021 Results assessing the proportion of APOBEC3F/3G defective viruses in PBMC from ARV-treated patients with prolonged virological suppression, presented at the 11th International AIDS Society Conference on HIV Science
  • 11 Mar 2020 Results (n=96) assessing factors between drug concentration and body weights in HIV-1-infections patients were presented at the 27th Conference on Retroviruses and Opportunistic Infections
  • 24 Feb 2020 Results of pharmacovirological analysis describing plasma residual HIV viraemia, cellular HIV reservoir size, blood plasma drug concentrations and their male genital tract penetration during the maintenance dual therapy dolutegravir + lamivudine published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top